title: Gardasil Vaccination for Recurrent Laryngeal Papillomatosis in Adult Men: First Report: Changes in HPV Antibody Titer.
abstract: BACKGROUND
  Patients with human papillomavirus (HPV) DNA-positive recurrent laryngeal papillomatosis commonly have repeated recurrences following surgery. The reason is suspected to be a mechanism by which latent HPV infection in the surrounding healthy mucosa reinfects the surgical site. It may be that production of HPV antibodies in the laryngeal mucosa with Gardasil injection could inhibit postoperative recurrence.
  
  
  METHODS
  This is a case series study.
  
  
  OBJECTIVE
  The purpose of this study was to examine whether Gardasil injection effectively inhibits recurrence. However, as a first report, we describe the antibody titers before and after vaccination.
  
  
  METHODS
  Gardasil was injected in 12 men (aged 32-74 years; mean age 47.9 years) with HPV-positive laryngeal papillomatosis. Serum antibody titers of HPV-6, -11, -16, and -18 were measured by a competitive Luminex-based immunoassay before the vaccination and 7 months after the start of the vaccination.
  
  
  RESULTS
  Each of the antibody titers was very low before vaccination, and they rose in all patients after the vaccination.
  
  
  CONCLUSIONS
  This finding demonstrates that antibody titers increase with Gardasil injection in post-adolescent males.
authors.affiliation: Department of Otorhinolaryngology, Nihon University Hospital, 1-6 Kandasurugadai, Chiyoda, Tokyo 101-8309, Japan.. Electronic address: mak@med.email.ne.jp.
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Makiyama
authors.affiliation: Department of Otorhinolaryngology, Nihon University Hospital, 1-6 Kandasurugadai, Chiyoda, Tokyo 101-8309, Japan.
authors.forename: Ryoji
authors.initials: R
authors.lastname: Hirai
authors.affiliation: Department of Otorhinolaryngology, Nihon University Hospital, 1-6 Kandasurugadai, Chiyoda, Tokyo 101-8309, Japan.
authors.forename: Hiroumi
authors.initials: H
authors.lastname: Matsuzaki
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000914:Antibodies, Viral / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D061809:Human Papillomavirus DNA Tests; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D030361:Papillomavirus Infections / Q000175:diagnosis / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D012141:Respiratory Tract Infections / Q000175:diagnosis / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D012737:Sex Factors; D013997:Time Factors; D016896:Treatment Outcome; D014611:Vaccination / Q000009:adverse effects
chemical_list: D000914:Antibodies, Viral; D015415:Biomarkers; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
keywords: Gardasil; antibody titers; quadrivalent HPV vaccine; recurrent laryngeal papilloma; recurrent respiratory papillomatosis